Approval Date: 8/31/2010
Principal Investigator: Padmaja Venuturumilli, MD
The purpose of this study is to evaluate if adding bevacizumab to standard chemotherapy for recurrent or metastatic head and neck cancer produces results that are better than those we would ordinarily expect.
- Confirmed squamous cell carcinoma of the head and neck (SCCHN)
- Metastatic or recurrent SCCHN of the head--incurable by surgery or radiation
- No chemotherapy for recurrent or metastatic SCCHN
Status of Clinical Trial:
open and enrolling